Breast Conserving Surgery in Combination With Targeted Intraoperative Radiotherapy Compared to Mastectomy for In-breast-tumor-recurrence

HANS-CHRISTIAN KOLBERG$^{1,2}$, HELENA NIESING$^{1}$, JAYANT S. VAIDYA$^{3}$, LEYLA AKPOLAT-BASCI$^{1}$, ABDRHMAN MAGUZ$^{1}$, OLIVER HOFFMANN$^{4}$, GYOERG LOEVEY$^{5}$, MILTIADES STEPHANOU$^{1}$ and CORNELIA KOLBERG-LIEDTKE$^{2,4}$

$^{1}$Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany;
$^{2}$Phaon Scientific GmbH, Wiesbaden, Germany;
$^{3}$Division of Surgery and Interventional Science, University College London, London, U.K.;
$^{4}$Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany;
$^{5}$Radiation Oncology, BORAD, Bottrop, Germany

Reprinted from
ANTICANCER RESEARCH 43: 733-739 (2023)
Breast Conserving Surgery in Combination With Targeted Intraoperative Radiotherapy Compared to Mastectomy for In-breast-tumor-recurrence

HANS-CHRISTIAN KOLBERG1,2, HELENA NIESING1, JAYANT S. VAIDYA3, LEYLA AKPOLAT-BASCI1, ABDRHMAN MAGUZ1, OLIVER HOFFMANN4, GYOERGY LOEVEY2, MILTIADES STEPHANOU1 and CORNELIA KOLBERG-LIETKE2,4

1Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany; 2Phaon Scientific GmbH, Wiesbaden, Germany; 3Division of Surgery and Interventional Science, University College London, London, U.K.; 4Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; 5Radiation Oncology, BORAD, Bottrop, Germany

Abstract. Background/Aim: Mastectomy is the standard treatment of in-breast-recurrence of breast cancer after breast conserving surgery (BCS) and external beam radiation therapy (EBRT). In selected cases, it is possible to preserve the breast if targeted intraoperative radiotherapy (TARGIT-IORT) can be given during the second lumpectomy. This is a comparative analysis of overall survival and quality of life (QoL). Patients and Methods: Patients in our database with in-breast-recurrence and either mastectomy or BCS and TARGIT-IORT were included. Identified patients were offered participation in a prospective QoL-analysis using the BREAST-Q questionnaire. The cohorts were compared for confounding parameters, overall survival, and QoL. Results: Thirty-six patients treated for in-breast-recurrence were included, 21 had received a mastectomy and 16 patients had received BCS with TARGIT-IORT. Mean follow-up was 12.8 years since primary diagnosis and 4.2 years since recurrence. Both groups were balanced regarding prognostic parameters. Overall survival was numerically longer for BCS and TARGIT-IORT, but the numbers were too small for formal statistical analysis. No patient had further in-breast-recurrence. Psychosocial and sexual wellbeing did not differ between both groups. Physical wellbeing was significantly superior for those whose breast could be preserved (p-value=0.021). Patient-reported incidence and severity of lymphedema of the arm was significantly worse in the mastectomy group (p=0.007). Conclusion: Preserving the breast by use of TARGIT-IORT was safe with no recurrence and no detriment to overall survival in our analysis and led to a statistically significant improvement in physical wellbeing and incidence of lymphedema. These data should increase the confidence in offering breast preservation after in-breast-recurrence of breast cancer.

Local recurrence-free survival after breast conserving therapy for stage I-III breast cancer, i.e., breast conserving surgery and breast irradiation, has been reported to be 89% after 5 years and 80% after 10 years of follow up (1). Patients remain at a risk for an ipsilateral in-breast tumor recurrence (IBTR) of 0.5% per year (2). The risk of local recurrence is significantly higher in patients younger than 70 than in older patients (3). The database guiding systemic treatment recommendations in the case of a local recurrence without distant disease is small. The only prospective trial investigating adjuvant chemotherapy in this situation, the CALOR trial, demonstrated a benefit in association with adjuvant chemotherapy only for hormone receptor negative patients (4). Data regarding the use of HER2-directed antibodies or tyrosine kinase inhibitors in the setting of an isolated local recurrence are missing and recommendations in this situation are based on extrapolations from early or metastatic breast cancer (5). The benefit of endocrine therapy in the situation of an endocrine responsive local recurrence is limited to disease-free survival without impact on overall survival (6-8). Not only is the systemic treatment approach in this situation subject to discussion and has to be decided individually, but the same is true for surgical treatment options. The more radical surgical approach (i.e.,

Correspondence to: Priv.-Doz. Dr. med. Hans-Christian Kolberg, Department of Gynecology and Obstetrics, Marienhospital Bottrop gGmbH, Josef-Albers-Str. 70, 46236 Bottrop, Germany. Tel: +49 20411061601, e-mail: hans-christian.kolberg@mhb-bottrop.de

Key Words: Breast cancer, in-breast-tumor-recurrence, IBTR, mastectomy, TARGIT-IORT, BREAST-Q, QoL.
mastectomy) results in a range of second local recurrence rates between 2.31% in comparably small datasets (9); however, it seems to be without prognostic impact if the regional lymph nodes are evaluated or not (10). The less radical solution of repeat breast conserving surgery without radiation leads to local failure in 19-50% (9). Interestingly a direct comparison of mastectomy and breast conserving surgery without radiation did not reveal significantly different rates of second recurrence in a series of 266 patients with a follow up of 51 months (breast conservation 38% vs. mastectomy 25%; p=0.27) (11). In another series comparing mastectomy with second breast conserving surgery with a median follow up of 70 months the difference in rates of second surgery in breast recurrence favoring mastectomy (4% versus 19%) did not influence overall and disease-free survival (12). A recent meta-analysis including 15 studies confirmed these results and demonstrated an increased rate of local failure for repeat breast conserving surgery compared to mastectomy but no impact on overall survival (13). Although the addition of whole breast irradiation to breast conserving surgery in case of a breast, which has already received a full course of radiation, was demonstrated to be feasible (14, 15), this approach was never really pursued due to fear of a high risk of severe toxicity not only for the breast tissue itself but also for adjacent structures, such as the lung. The application of techniques of partial breast irradiation to avoid an elevated toxicity risk in this situation yielded good control rates, acceptable toxicity and good cosmesis for external partial re-irradiation (16), brachytherapy (17-19) and for targeted intraoperative radiotherapy (TARGIT-IORT) with the 50kV-XRay-device (20, 21). These data did not only lead to the integration of breast conserving surgery in combination with partial breast irradiation in national guidelines as an option for selected patients in case of IBTR (and not as a replacement for mastectomy in general) (22-24), but have also convinced breast surgeons and radiation oncologists to offer this option to patients who want to preserve their breast (25).

Results regarding quality of life (QoL) after repeat BCS are not conclusive. In a study including patients after second BCS for IBTR and with and without partial breast irradiation (PBI) demonstrated a QoL benefit for repeat BCS compared to mastectomy (26) whereas a trial comparing BCS and TARGIT-IORT with mastectomy with and without reconstruction found comparable QoL using the BREAST-Q™ questionnaire in all three groups (27). Here, we are presenting an analysis comparing long-term outcome, patient-reported side effects, and QoL between patients who received BCS and TARGIT-IORT and patients who received a mastectomy for IBTR.

Patients and Methods

This study included patients who were treated for IBTR after breast conserving surgery and whole breast irradiation in our certified breast cancer center between 2014 and 2020 and who had received either mastectomy or BCS and TARGIT-IORT for IBTR. Both options were discussed with the patients and patients chose their preferred procedure. Patients with distant recurrence and patients with breast reconstruction after mastectomy for IBTR were excluded from this analysis. All patients received a mammography, breast and axilla ultrasound, CT scans of the thorax and abdomen and a bone scan prior to surgery. Data regarding patient characteristics at the time of recurrence and follow-up were extracted from the patient files and transferred into an Excel-file after anonymization.

The analysis includes a retrospective part regarding patient characteristics and outcome parameters and a prospective part regarding QoL analysis. Patients had signed a written informed consent authorizing the use of their follow-up data for scientific reasons at the time of surgery for IBTR. For the prospective QoL analysis, patients were contacted via mail and offered participation in the study. Written informed consent, patients received the German version of the BREAST-Q™ questionnaire. The results of the completed BREAST-Q™ questionnaires were also transferred into the anonymized Excel-file.

Patient and tumor characteristics analyzed at the time of recurrence included (all at the time of IBTR) age, diameter, estrogen receptor status (ER), progesterone receptor status (PR), HER2neu status, nodal status, and use of neoadjuvant therapy for IBTR. Outcome parameters analyzed were overall survival defined as death by any cause after time of primary diagnosis and time of IBTR.

Parameters analyzed from the results of the BREAST-Q™ questionnaires were psychosocial, sexual, and physical wellbeing, lymphedema of the arm on the side of surgery, satisfaction with breast surgeon, medical team, and office staff, and adverse effects of radiation.

Values in the BREAST-Q™ questionnaires were added and transformed into a sum score between 0 and 100 with a higher sum score indicating a higher QoL. As an exception from this method, the item “lymphedema of the arm on the side of surgery” was transformed into a scale from 1 to 3 with 3 meaning that the patient had not suffered from a lymphedema at any time.

Mastectomy was performed as a modified radical mastectomy with removal of the skin, breast tissue, and fascia of the musculus pectoralis major. Patients with breast reconstruction were not included in this analysis. Breast conserving surgery was performed as segmentectomy. TARGIT-IORT was performed with the 50kV X-ray source Intrabeam™ (Carl Zeiss meditec, Oberkochen, Germany). The applied radiation dose was 20 Gray at the surface of the applicator resulting in 5-6 Gray in a depth of 1 cm. Axillary surgery was not performed as a standard procedure, only in cases of involved lymph nodes these were removed.

The two cohorts (mastectomy/BCS and TARGIT-IORT) were compared for confounding parameters, OS from primary diagnosis, and time of IBTR and QoL.

Statistical analysis. After transfer of the retrospective and prospective data into the anonymized Excel-file (Microsoft Excel®, Version 16.56, 2021) the statistical analysis was performed using the software SPSS® Statistics Version 28 (IBM Corp. Released 2021, IBM SPSS Statistics for Macintosh, Version 28.0. Armonk, NY, USA).

Hormone receptor and HER2neu status, tumor morphology, nodal status, and the use of neoadjuvant therapy were compared with the Chi-square test in case of ≥5 observations and with Fisher’s exact test in case of <5 observations. Metrical variables, such as
Results

In total, 36 patients treated for IBTR were included in this analysis, 21 had a mastectomy while 15 patients chose to preserve their breast and were treated with BCS and TARGIT-IORT in compliance with an interdisciplinary tumor board decision. The Ethics Commission of the Faculty of Medicine at the University of Duisburg-Essen approved the project on June 23rd, 2021 (Approval No: 21-10061-BO).

Mean follow-up was 12.8 years since primary diagnosis and 4.2 years since recurrence. We observed no statistically significant differences between both groups regarding age, ER, PR, HER2neu, tumor size, nodal status, and the use of neoadjuvant therapy at the time of recurrence. The results of the comparison of patient characteristics at the time of recurrence can be found in Table I.

One patient in the BCS and TARGIT-IORT group (6.7%) and 3 patients in the mastectomy group (14.3%) died during follow-up. Overall survival was numerically longer for BCS and TARGIT-IORT either calculated from primary diagnosis (mean BCS + TARGIT-IORT 24.4 years versus mastectomy 23.4 years) or from recurrence (mean BCS + TARGIT-IORT 7.7 years versus mastectomy 6.4 years), however, these differences were not statistically significant. No patient had a second local recurrence during follow-up. The results of the outcome analysis can be found in Table II.

Twelve of the 21 patients in the mastectomy group and 10 of the 15 patients in the BCS and IORT group returned the BREAST-Q questionnaire. Eight patients refused participation in the prospective QoL analysis, four patients had died, and two patients did not react at all, but were alive according to information from their general practitioners. Use of the BREAST-Q questionnaire, authored by Drs. Klassen, Pusic and Cano, was made under license from Memorial Sloan Kettering Cancer Center, New York, NY, USA. Psychosocial wellbeing, sexual wellbeing, and satisfaction with breast surgeon, office team, and medical staff did not differ between both groups. Physical wellbeing was superior for those whose breast could be preserved. The median score for this item in the BCS and TARGIT-IORT group was 91.0 [interquartile range (IQR)=71.0-100.0] versus 66.0 (IQR=57.2-100.0) for the mastectomy group. This difference was statistically significant with a p-value of 0.021. Whereas other side effects were comparable without significant differences in both groups, patient-reported incidence and severity of lymphedema of the arm on the side of surgery was significantly worse in the mastectomy group with a score of 2.0 (IQR=2.0-3.0) compared to 3.0 (IQR=3.0-3.0) in the BCS and TARGIT-IORT group. This difference was statistically significant with a p-value of 0.007. The full set of analyzed items from the BREAST-Q questionnaires and the corresponding scores are displayed in Table III.

Discussion

Early breast cancer carries a good prognosis with local recurrence-free survival at 10-years of about 80% (1). Because of this high rate of long-term survival, questions of patient satisfaction, long-term side effects, and QoL have come more and more into focus. Patient-reported outcomes are considered to be at least as if not more important than clinical and photographic assessments of results after breast conserving therapy (28). QoL and self-esteem are reported to be superior in patients treated with BCS compared to mastectomy for early breast cancer at the time of primary diagnosis. Interestingly this did not change if patients received a breast reconstruction (29). In the recurrent situation, patients are also reporting a better QoL if treated with a second breast conserving operation compared to mastectomy (30-32).
Intraoperative radiotherapy with a 50 kV X-ray-source (TARGIT-IORT) has become one standard of care in the local treatment of early breast cancer as an anticipated boost (33) but also as definitive radiation (34). This has led to the integration of TARGIT-IORT into national guidelines and recommendations (35) and it is also used in indications when radiation is problematic e.g., in patients with implants who do not want them to be removed in the course of BCS (36). In Germany, access to treatment with the INTRABEAM™-device is available in over 50 certified breast cancer centers.

In our analysis, overall survival was longer in the group of patients receiving BCS and TARGIT-IORT for IBTR compared to the group of patients with a mastectomy, although this result did not reach statistical significance. This trend for a better outcome without statistical significance has also been reported previously in studies comparing BCS and TARGIT-IORT with mastectomy in cases of IBTR (27). Although the numerical results hint to a benefit of BCS and TARGIT-IORT, we recommend a very cautious interpretation of these data. However, we believe it is safe to acknowledge that BCS and TARGIT-IORT is not detrimental to overall survival compared to the standard of care mastectomy in cases of IBTR and can thus be regarded a safe alternative.

Regarding QoL and patient reported toxicity, our data demonstrated a significantly superior physical wellbeing in the BCS and TARGIT-IORT. This is in line with other data in this situation, demonstrating that TARGIT-IORT is associated with superior (26) or at least non-inferior (26) QoL of BCS and partial breast irradiation compared to mastectomy. The study that did not demonstrate a superior QoL included three groups (BCS + TARGIT-IORT versus mastectomy without reconstruction versus mastectomy with reconstruction) whereas our inclusion criteria did not include patients with reconstruction after mastectomy. It is possible that the group of patients with mastectomy and reconstruction led to the differing findings regarding QoL because these patients are exposed to a higher possibility of postoperative complications and this may have influenced the analysis of QoL. In another retrospective series including patients with primary tumors the failure of reconstructions was significantly associated with the application of radiation (37) and a failed reconstruction can be expected to have a detrimental effect on how patients feel about their therapy.

We also could demonstrate a significantly lower rate of postoperative lymphedema in the group of patients who received BCS and TARGIT-IORT compared to mastectomy. To our knowledge, this is the first time this benefit is reported. Considering the fact that lymphedema does not only have the expected effects on arm movement and pain but also leads to a rate of 58.8% of sleep disturbances and a rate of 29.7% of...
depression in affected patients (38), this result should be mentioned in the process of decision making in cases of IBTR.

Of course, our analysis has limitations that have to be kept in mind when interpreting the data. It was a retrospective analysis and the patient numbers are small. However, prospective data in this situation are missing and comparable analyses have patient numbers in the same range. Although studies like ours have to be interpreted with caution, they give confidence when discussing the alternatives of mastectomy and BCS and TARGIT-IORT with a patient in case of an IBTR.

The majority of patients with breast cancer including those with local recurrence are highly reluctant to lose their breast. In our analysis, we found that breast preservation by use of TARGIT-IORT was safe with no re-recurrence and no detriment to overall survival. This approach led to a statistically significant improvement in physical wellbeing as well as the rate of lymphedema. Our results carry the potential to increase the confidence in offering breast preservation in combination with TARGIT-IORT for local therapy of IBTR of breast cancer.

Conflicts of Interest

HCK has received honoraria from Pfizer, Novartis, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, TEVA, Theracloon, Janssen-Cilag, GSK, LIV Pharma, Lily, SurgVision, Onkowissen, Gilead, Daiichi Sankyo and MSD, travel support from Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, Daiichi Sankyo, Tesaro and owns stock of Theracloon SA and Phaon Scientific GmbH. HN has nothing to disclose. JSV has nothing to disclose. LAB has nothing to disclose. AM has nothing to disclose. OH has nothing to disclose. GL has nothing to disclose. MS has nothing to disclose. CKL reports stock by Phaon Scientific, honoraria by Roche, AstraZeneca, Celgene, Novartis, Pfizer, Lilly, Hexal, Amgen, SonoScape, consulting to Roche, Novartis, Pfizer, Celgene, Phaon Scientific; research funding by Roche, Novartis, Pfizer as well as travel and accommodation by Roche, Daiichi Sankyo.

Authors’ Contributions

The design of the analysis was developed by HCK, CKL, and HN. Data collection and statistical analysis were performed by HCK and HN. Interpretation of the data, writing and correction of the manuscript were performed by HCK, HN, JSV, LAB, AM, OH, GL, MS, and CKL. All Authors approved the final version of this manuscript.

Acknowledgements

Use of the BREAST-Q™ questionnaire, authored by Drs. Klassen, Pusic and Cano, was made under license from Memorial Sloan Kettering Cancer Center, New York, U.S.A.

References

10 Poodt IGM, Vughts G, Schipper R, Roumen RMH, Rutten HJT, Maaskant-Braat AJG, Voogd AC, Nieuwenhuijzen GAP and


22 Diagnostik und Therapie fruher und fortgeschrittener Mammakarzinome. Available at: https://www.ago-online.de/fileadmin/ago-online/downloads/leitlinien/kommission_mamma/2022/Einzeldateien_Literatur/AG0_2022D_16_Nachsorge_REF.pdf [Last accessed on December 14, 2022]


35 Adjuvante Strahlentherapie. Available at: https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2022/Einzeldateien/AGO_2022D_13_Adjuvante_Strahlentherapie.pdf [Last accessed on November 20, 2022]


Received December 5, 2022
Revised December 13, 2022
Accepted December 14, 2022
Instructions for Authors 2023

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. Each article should include a concrete conclusion constituting a “new piece of knowledge” backed up by scientific evidence. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

AR provides for the prompt print and online publication of accepted articles, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

AR is a hybrid open-access journal (a subscription journal in which some of the articles are open access). All articles that are published as open access are with gold OA, which means that the final published version is permanently and freely available to anyone. Our open access articles are distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

UKRI Open Access Policy. UKRI-funded Authors retain the right to distribute the final published version of their accepted article, such as via an institutional and/or subject repository (e.g. EuropePMC), under a Creative Commons Attribution 4.0 International (CC BY 4.0) licence (https://creativecommons.org/licenses/by/4.0/).

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work (without supplementary data), and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. Excess pages are charged US$ 230.00 each. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work or before the Acknowledgements); (b) Abstract not exceeding 250 words, organized according to the following headings: Background/Aim – Materials and Methods/ Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/ Patients and Methods; (e) Results; (f) Discussion; (g) Conflicts of Interest; (h) Authors’ Contributions; (i) Acknowledgements; (j) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures (graphs and photographs). All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Figures should be prepared at a width of 8 or 17cm with eligible symbols, lettering and numbers. The number of each figure must be indicated. Pages that include color figures are subject to color charges (US$350.00 per page).

Tables. All tables should appear at the end of the submitted document file. Each table may have 2-10 vertical columns. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iiar@iiar-anticancer.org) within 24 hours.

Erratum. An erratum is published to correct any error(s) that might have been introduced to the article by the publisher during the publication process. Authors who may notice an error in the final published article should contact directly the Editorial Office.

Corrigendum. A corrigendum is published to change a part or to correct any error(s) that might have been introduced by the author(s). Authors should contact our Editorial Office, and our Editor will decide on the appropriate course of action.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 5 days from submission, the author should contact the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for peer-review (single-blind) in confidence to two-three suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   • The Instructions to Authors must be followed in every detail.
   • The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   • The presentation of results should be simple and straightforward in style. Results and Discussion should not be combined into one section.
   • Results given in figures should not be repeated in tables.
   • Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   • Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   • Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   • Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by… authors, year).
   • References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
   • By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably in red. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. All Authors will be asked to supply author contribution and conflict of interest forms.

10. Articles submitted to AR may be rejected without review if:
   • they do not fall within the journal's policy.
   • they do not follow the instructions for authors.
   • language is unclear.
   • results are not sufficient to support a final conclusion.
   • results are not objectively based on valid experiments.
   • they repeat results already published by the same or other authors before the submission to AR.
   • plagiarism is detected by plagiarism screening services.

   (Rejection rate (2022): 71%).

11. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

12. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

13. Authors who wish to organize and edit a special issue on a particular topic should contact the Managing Editor.

14. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2023 – International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.